MMT-205 / Curacle, MabTics, Sera Medicines, Memento Medicines - LARVOL DELTA

A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization. (PubMed, J Transl Med) - "These findings demonstrate that a therapeutic strategy combining direct Tie2 activation and VEGF blockade may provide improved therapeutic potential compared to neutralizing VEGF alone or Ang2 and VEGF, representing a promising therapeutic strategy that warrants further validation for the treatment of various ocular diseases."

Journal • Ophthalmology • Retinal Disorders • FLT1 • NOS3

Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease (Ophthalmology Times) - "According to the company, proceeds from the financing will fund IND-enabling studies, with clinical trials expected to begin in 2027."

Financing • New trial • Age-related Macular Degeneration • Diabetic Macular Edema

Curacle and MabTics said preclinical data showed MT-103 performed better than Eylea and a surrogate version of Vabysmo in reducing vascular leakage and abnormal blood vessel growth (Korea Biomedical Review) - "The data were presented on May 3 at ARVO 2026 in Denver."

Preclinical • Ophthalmology

Curacle and MabTics have licensed a preclinical retinal disease antibody to U.S.-based Memento Medicines in a global deal worth up to $1.08 billion, giving the two Korean biotech companies an early win in one of the fastest-moving areas of eye-disease drug development (Korea Biomedical Review) - "The deal covers MT-103, a bispecific antibody designed for retinal diseases, including wet age-related macular degeneration and diabetic macular edema, two conditions that can cause vision loss by damaging blood vessels in the eye. The agreement is worth up to $1.08 billion, including an $8 million upfront payment and milestones tied to development, regulatory approval, and commercialization, according to a regulatory filing by Curacle, a Kosdaq-listed drug developer focused on vascular diseases."

Licensing / partnership • Diabetic Macular Edema • Wet Age-related Macular Degeneration

A novel tri-functional antibody integrating Tie2 activation, VEGF inhibition, and Ang-2 blockade delivers superior retinal vascular outcomes beyond current therapies (ARVO 2026) - "Results MT-103 robustly activated Tie2, more effectively inhibited VEGF signaling, and reduced endothelial hyperpermeability compared with faricimab and other comparators...In multiple laboratory and animal studies, MT-103 improved vessel stability, reduced leakage and inflammation, and preserved key supporting cells more effectively than existing treatments. These findings suggest that MT-103 could offer a promising new therapeutic option for people with retinal vascular diseases."

Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders

Curacle, Shareholder Allocation Paid-in Capital Increase Decision… Expected Value Increase Through Progress in R&D Development of Major Pipelines such as CU06 and CU71 [Google translation] (Hankyung) - "Curacle...held a board meeting on the 16th and decided to increase capital through a public offering of common stock after allocating a total of 28.6 billion won to shareholders. The number of shares to be issued is 7 million, which is approximately 50% of the current number of issued shares...Curacle plans to focus the funds secured through this paid-in capital increase on R&D costs and operating funds for its main pipelines. The main uses are: Clinical phase 2b for retinal disease treatment drug CU06, Clinical phase 1 for Alzheimer's disease treatment drug CU71, and R&D progress for main pipelines such as CU01, MT-101, and MT-103....CU06 is a first-in-class new drug candidate under development as an oral retinal disease treatment, and is preparing to apply for an IND (clinical trial plan) for a phase 2b clinical trial in the second half of this year."

Financing • New P2b trial • Alzheimer's Disease • Diabetic Nephropathy • Retinal Disorders

Mabtics-Curacle, 'MT-101' and 'MT-103' domestic and PCT patent applications [Google translation] (HIT News) - "Mabtics announced on the 4th that it has completed domestic and PCT (Patent Cooperation Treaty) patent applications for antibody treatments 'MT-101' and 'MT-103', which it is jointly developing with Curacle. Through this, it is accelerating global commercialization...According to the company, MT-101 is a Tie2 activating antibody under development as a treatment for acute kidney injury (AKI) and chronic renal failure (CKD)...MT-103 is a dual antibody-based retinal disease treatment that combines a Tie2-activating antibody and an anti-VEGF antibody, and is being developed for indications such as wet macular degeneration and diabetic macular edema."

Patent • Acute Kidney Injury • Chronic Kidney Disease • Diabetic Macular Edema • Macular Degeneration

Curacle, Daesung Pharmtech merger… “High correlation and growth potential” [Google translation] (Medipana) - "According to the public notice on the 6th, the merger will be conducted in the form of a small-scale merger through the issuance of new shares, and the merger date is May 14. In particular, through this merger, Curacle expects to further strengthen its financial soundness while also combining Daesung Pharmtech’s raw pharmaceutical ingredient expertise with Curacle’s R&D capabilities, thereby generating high synergy effects....Ophthalmology is an area where Curacle is developing its core pipelines, such as 'CU06 (oral treatment for retinal diseases)' and 'MT-103 (dual antibody for retinal diseases)', and this merger is expected to enable close collaboration by utilizing networks between new drug development and raw pharmaceutical ingredients businesses in the future."

M&A • Retinal Disorders